Bayer Kogenate FS Free Trial Program Fails To Include Labeling, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The CBER ad division letter cites the promotional materials for lack of risk information and failure to provide adequate direction for use.